Literature DB >> 19031019

Activation of dendritic cells by toll-like receptors and C-type lectins.

Sandra S Diebold1.   

Abstract

As sentinels of the immune system, dendritic cells (DC) scan their environment for the presence of pathogens. DC sense pathogens either directly or indirectly via endogenous factors such as cytokines and chemokines, which are produced by other cell types in response to infection. Although indirect signals in form of endogenous factors alert DC, direct activation of DC by pathogen-associated molecular patterns (PAMP) is crucial for the induction of primary T cell responses. Direct recognition of PAMP is mediated by pattern recognition receptors (PRR) such as Toll-like receptors (TLR) and C-type lectin receptors (CLR). The molecular patterns that are recognized by these receptors are indispensable for the life cycle of the pathogens, and their structure or cellular localization is different from that of the host. TLR detect cell-wall components of bacteria, fungi, and protozoa at the cell surface or bacterial and viral nucleic acid structures in a specialized endosomal compartment, while CLR that are involved in pattern recognition bind to carbohydrate structures associated with pathogens.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19031019     DOI: 10.1007/978-3-540-71029-5_1

Source DB:  PubMed          Journal:  Handb Exp Pharmacol        ISSN: 0171-2004


  22 in total

1.  Effects of antigen-expressing immunostimulatory liposomes on chemotaxis and maturation of dendritic cells in vitro and in human skin explants.

Authors:  Anastasia Lanzi; Cynthia M Fehres; Tanja D de Gruijl; Yvette van Kooyk; Enrico Mastrobattista
Journal:  Pharm Res       Date:  2013-09-26       Impact factor: 4.200

2.  Ex vivo antigen-pulsed PBMCs generate potent and long lasting immunity to infection when administered as a vaccine.

Authors:  Sudeep Kumar; Raju Sunagar; Giang Pham; Edmund J Gosselin; David Nalin
Journal:  Vaccine       Date:  2017-01-06       Impact factor: 3.641

3.  Immunogenicity of protein therapeutics: The key causes, consequences and challenges.

Authors:  Matthew P Baker; Helen M Reynolds; Brooke Lumicisi; Christine J Bryson
Journal:  Self Nonself       Date:  2010-10

4.  Dendritic cells transfected with Her2 antigen-encoding RNA replicons cross-prime CD8 T cells and protect mice against tumor challenge.

Authors:  Birgit Edlich; Leah J Hogdal; Barbara Rehermann; Sven-Erik Behrens
Journal:  Vaccine       Date:  2010-09-29       Impact factor: 3.641

5.  Memory CD4+ T cells are required for optimal NK cell effector functions against the opportunistic fungal pathogen Pneumocystis murina.

Authors:  Michelle N Kelly; Mingquan Zheng; Sanbao Ruan; Jay Kolls; Alain D'Souza; Judd E Shellito
Journal:  J Immunol       Date:  2012-11-30       Impact factor: 5.422

6.  B cell infection and activation by rabies virus-based vaccines.

Authors:  Andrew G Lytle; James E Norton; Corin L Dorfmeier; Shixue Shen; James P McGettigan
Journal:  J Virol       Date:  2013-06-12       Impact factor: 5.103

7.  Transcriptomic analysis of the temporal host response to skin infestation with the ectoparasitic mite Psoroptes ovis.

Authors:  Stewart T G Burgess; David Frew; Francesca Nunn; Craig A Watkins; Tom N McNeilly; Alasdair J Nisbet; John F Huntley
Journal:  BMC Genomics       Date:  2010-11-10       Impact factor: 3.969

8.  Analysis of the acute phase responses of serum amyloid a, haptoglobin and type 1 interferon in cattle experimentally infected with foot-and-mouth disease virus serotype O.

Authors:  Carolina Stenfeldt; Peter M H Heegaard; Anders Stockmarr; Kirsten Tjørnehøj; Graham J Belsham
Journal:  Vet Res       Date:  2011-05-18       Impact factor: 3.683

9.  Effects of Lansoprazole on the Lipopolysaccharide-Stimulated Toll-Like Receptor 4 Signal Transduction Systems: A Study Using the 293hTLR4/MD2-CD14 Cells.

Authors:  Tadashi Ohara; Yuhsaku Kanoh; Keiichi Yoshino; Masaki Kitajima
Journal:  J Clin Biochem Nutr       Date:  2009-08-28       Impact factor: 3.114

Review 10.  Tolerogenic dendritic cell therapy for rheumatoid arthritis: where are we now?

Authors:  C M U Hilkens; J D Isaacs
Journal:  Clin Exp Immunol       Date:  2013-05       Impact factor: 4.330

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.